For moderate to severe ulcerative colitis (UC) in adult TNFi-IR patients.1

D O S I N G  &

L A B  M O N I T O R I N G

DOSING &

LAB MONITORING

ONE PILL. ONCE-DAILY.

 

IR=intolerance or inadequate response;
TNFi=tumor necrosis factor inhibitor

Dosing
dosing

RINVOQ is a once-daily pill that comes in three dosage strengths

One strength for induction and two strengths for maintenance

45 mg QD pill bottles

INDUCTION

The recommended induction dose of RINVOQ is 45 mg QD for 8 weeks.

30 mg or 15 mg QD pill bottles

MAINTENANCE

The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily.

A dose of 30 mg once daily may be considered for patients with refractory, severe or extensive disease.

Discontinue if an adequate therapeutic response is not achieved with the 30 mg dose.

Use the lowest effective dose needed to maintain response.

INDUCTION

45 mg QD pill bottles

The recommended induction dose of RINVOQ is 45 mg QD for 8 weeks.

MAINTENANCE

The recommended dose of RINVOQ for maintenance treatment is 15 mg once daily.

A dose of 30 mg once daily may be considered for patients with refractory, severe or extensive disease.

Discontinue if an adequate therapeutic response is not achieved with the 30 mg dose.

Use the lowest effective dose needed to maintain response.

Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and cyclosporine.

Dosing for Renal/Hepatic Impairment & Drug Interactions
Download Dosing Guide

Administration1

  • Instruct patients to take one pill, once daily.1
  • Ensure pill is taken whole. Do not chew, crush, or split.1
  • RINVOQ can be taken with or without food. Advise patients to avoid food or drink containing grapefruit during treatment with RINVOQ.1
Footnotes and definitions
Lab monitoring and dosing considerations

Lab monitoring and dosing considerations1

Perform lab testing for:

Lab monitoring and dosing considerations

INTERRUPT IF PATIENT DEVELOPS A SERIOUS OR OPPORTUNISTIC INFECTION.

*Treatment can be initiated or restarted after levels return above specified values, drug-induced liver injury diagnosis is excluded, or infection is controlled.1

Footnotes and definitions

Interested to learn about safety data for RINVOQ?

See RINVOQ’s safety data across clinical trials

See safety profile